全文获取类型
收费全文 | 2614篇 |
免费 | 167篇 |
国内免费 | 77篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 182篇 |
妇产科学 | 32篇 |
基础医学 | 328篇 |
口腔科学 | 77篇 |
临床医学 | 290篇 |
内科学 | 555篇 |
皮肤病学 | 77篇 |
神经病学 | 215篇 |
特种医学 | 400篇 |
外科学 | 160篇 |
综合类 | 44篇 |
预防医学 | 116篇 |
眼科学 | 31篇 |
药学 | 116篇 |
2篇 | |
肿瘤学 | 232篇 |
出版年
2023年 | 5篇 |
2022年 | 8篇 |
2021年 | 18篇 |
2020年 | 20篇 |
2019年 | 26篇 |
2018年 | 53篇 |
2017年 | 37篇 |
2016年 | 31篇 |
2015年 | 56篇 |
2014年 | 58篇 |
2013年 | 77篇 |
2012年 | 77篇 |
2011年 | 78篇 |
2010年 | 113篇 |
2009年 | 115篇 |
2008年 | 83篇 |
2007年 | 119篇 |
2006年 | 97篇 |
2005年 | 74篇 |
2004年 | 55篇 |
2003年 | 47篇 |
2002年 | 59篇 |
2001年 | 59篇 |
2000年 | 51篇 |
1999年 | 45篇 |
1998年 | 143篇 |
1997年 | 161篇 |
1996年 | 138篇 |
1995年 | 120篇 |
1994年 | 119篇 |
1993年 | 104篇 |
1992年 | 39篇 |
1991年 | 42篇 |
1990年 | 47篇 |
1989年 | 63篇 |
1988年 | 55篇 |
1987年 | 47篇 |
1986年 | 54篇 |
1985年 | 49篇 |
1984年 | 26篇 |
1983年 | 16篇 |
1982年 | 24篇 |
1981年 | 29篇 |
1980年 | 25篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 22篇 |
1976年 | 27篇 |
1975年 | 14篇 |
1904年 | 3篇 |
排序方式: 共有2858条查询结果,搜索用时 31 毫秒
1.
JM Martín† L Calduch† C Monteagudo‡ I Molina† D Ramón† V Alonso† E Jordᆠ《Journal of the European Academy of Dermatology and Venereology》2006,20(4):428-431
Cutaneous plasmacytosis is a rare disorder characterized by a benign proliferation of mature plasma cells that appears as multiple dark-brown to purplish skin lesions, often associated with polyclonal hypergammaglobulinaemia. We present the case of a 55-year-old Caucasian man who suffered from a cutaneous plasmacytosis associated with two different carcinomas. Cutaneous plasmacytosis seems to be a reactive process because most cases reported are not associated with any apparent underlying disease. Nevertheless, because few reported cases were associated with malignancies, screening of additional neoplasms would be justified. 相似文献
2.
3.
Jan de Lange Thomas Putters Erik M Baas Johan M van Ingen 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2007,104(6):841-845
OBJECTIVE: The purpose of this study was to evaluate the potential benefit of an ultrasonic device in apical surgery on the outcome of treatment. STUDY DESIGN: A randomized prospective design was used in a standardized treatment protocol. Patients were allocated to treatment with an ultrasonic device (P-Max Newtron) or treatment with a bur in an otherwise similar protocol. One year after treatment the results were evaluated by 2 oral and maxillofacial surgeons who were blinded for the therapy. RESULTS: Out of a total group of 399 patients who were included in the study, adequate follow-up could be obtained in 290 patients. The overall success rate in the ultrasonic group was 80.5% and in the group treated with a bur 70.9% (P = .056). In molars, the difference in success rate was significant (P = .02). CONCLUSION: The use of an ultrasonic device in apical surgery improved the outcome of treatment. In molars this effect was significant. 相似文献
4.
Dr. S. Eggstein MD G. Manthey MT T. Hirsch PhD F. Baas MA B. U. V. Specht MD E. H. Farthmann MD 《Digestive diseases and sciences》1996,41(6):1069-1075
Epidermal growth factor receptors (EGFR) andras mutations are known to play a significant role in controlling cell growth and tumor promotion. Both of them transmit mitogenic signals to the nucleus by activation of Raf-1 kinase. In this study, the expression of EGFR and mutant Ras proteins, and, for the first time, the expression, phosphorylation and kinase activity of Raf-1 kinase have been determined in paired samples of colorectal cancer and mucosa. The tumor and mucosa samples did not differ significantly with regard to Raf-1 kinase content and activity. A major difference between tumors and mucosa was found, however, in the phosphorylation of Raf-1. Most of the mucosa samples (13/20), but only 1/20 of the cancer samples, contained hyperphosphorylated Raf-1. EGFR were significantly (p=0.0025) decreased in the tumors. The decreased phosphorylation of Raf-1 in colonic carcinomas could be the result of activation of Raf-1 phosphatases or inactivation of kinases phosphorylating Raf-1. New forms of treatment based on EGFR overexpression do not seem to be suitable for the majority of colonic cancers.This work was supported by the state of Baden-Württemberg (Verbundforschungsprojekt: Aufklärung von Mechanismen der Tumorentstehung und Tumorabwehr). 相似文献
5.
JM Vilanova J Figueras-Aloy J Roselló G Gómez E Gelpí R Jiménez 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(5):588-592
The aim of this study was to evaluate the cerebral synthesis of eicosanoids in the asphyctic newborn and to investigate the relation between the prostanoid profiles in cerebrospinal fluid (CSF) and the appearance and severity of hypoxic-ischaemic encephalopathy (HIE). Levels of 6-keto-PGF 1-α, TXB2 , PGE2 and PGF2-α in CSF were measured in 40 full term newborns during the first day of life. Thirty of these newborns had birth asphyxia and were divided into three groups: 10 without HIE, 12 with mild HIE and 8 with moderate-severe HIE. They were compared to a control group of 10 non-hypoxic newborns. Determinations of the metabolites in CSF were performed by RIA and expressed as pg/ml (mean ± SD). The CSF TXB2 (thromboxane A2 metabolite) in asphyxiated newborns was always higher than in the control group (28.12 ± 10.6), and related to the severity of HIE ( p = 0:005): without HIE (50.84 ± 16.4; p = 0:02), mild HIE (80.65 ± 12.64; p ± 0:01) and moderate-severe HIE (178.14 ± 20.5; p < 0:01). The CSF 6-keto-PGF 1-α (prostacyclin metabolite) in asphyxiated newborns was always higher than in the control group (80.55 ± 12.56), but indirectly related to the severity of HIE: without HIE (240.95 ± 28.12; p < 0:01), mild HIE (183.65 ± 30.1; p < 0:01) and moderate-severe HIE (140.55 ± 25.12; p < 0:01). In the moderate-severe HIE group, the increase in TXB2 was higher than the rise in 6-keto-PGF 1-α . 相似文献
6.
7.
Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma 总被引:9,自引:3,他引:6
Weisenburger DD; Gordon BG; Vose JM; Bast MA; Chan WC; Greiner TC; Anderson JR; Sanger WG 《Blood》1996,87(9):3860-3868
Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a distinct clinicopathologic entity associated with the t(2;5) (p23;q35). However, the specificity of t(2;5) for ALCL has not been carefully studied. Therefore, we performed a detailed analysis of all cases of ALCL with abnormal cytogenetics results in the Nebraska Lymphoma Study Group registry, as well as all other cases of non-Hodgkin's lymphoma with t(2;5) in the registry. We found the t(2;5) in only five of 10 cases of ALCL, four of whom were young patients. However, we also found the t(2;5) in 11 other cases of nonanaplastic lymphoma, including eight children with typical peripheral T-cell lymphomas of various types. The t(2;5) was also found in three older adults with B-cell lymphomas of various types. Thus, the t(2;5) was not specific for CD30+ ALCL. However, t(2;5) may define a clinicopathologic entity in children and young adults characterized by variable morphologies with a T-cell or indeterminate phenotype, CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent response to therapy, including bone marrow transplantation for relapsed disease. The clinical relevance of the t(2;5) in older patients requires further study. 相似文献
8.
9.
10.
Impact of randomized trials comparing conventional and endovascular abdominal aortic aneurysm repair on clinical practice. 总被引:1,自引:0,他引:1
Annette F Baas Diederick E Grobbee Jan D Blankensteijn 《Journal of endovascular therapy》2007,14(4):536-540
PURPOSE: To report a retrospective study into the effects of trials on clinical decision-making regarding abdominal aortic aneurysm (AAA) patients suitable for both conventional open (OR) and endovascular aneurysm repair (EVAR). METHODS: A questionnaire was sent to 1400 Dutch surgeons and trainees. Interviewees had to choose between OR and EVAR for AAA patients with and without comorbidity. Specifically, their preferences before and after the publication of 2 randomized trials (EVAR-1 and DREAM) were polled. RESULTS: Of the 524 (37%) questionnaires returned, 223 (43%) respondents treated AAA patients. Before publication of the trials, 160 (72%) preferred OR for the patient without comorbidity and 169 (76%) preferred EVAR for the patient with comorbidity. In total, 72 (32%) respondents changed their preference after the trials were published; however, there was no overall major shift. Focusing on the different cases revealed that the OR preference was significantly enhanced for the patient without comorbidity (p<0.01), while the EVAR preference was significantly enhanced for the patient with comorbidity (p<0.05). CONCLUSION: The randomized trials have not induced major overall changes in surgical decision-making for AAA patients suitable for both EVAR and OR. 相似文献